[go: up one dir, main page]

ATE497003T1 - Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht - Google Patents

Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht

Info

Publication number
ATE497003T1
ATE497003T1 AT03767876T AT03767876T ATE497003T1 AT E497003 T1 ATE497003 T1 AT E497003T1 AT 03767876 T AT03767876 T AT 03767876T AT 03767876 T AT03767876 T AT 03767876T AT E497003 T1 ATE497003 T1 AT E497003T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
pharmaceutical composition
obesity
medication
Prior art date
Application number
AT03767876T
Other languages
English (en)
Inventor
Valerie Compan
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE497003T1 publication Critical patent/ATE497003T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03767876T 2002-10-31 2003-10-31 Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht ATE497003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213725A FR2846559B1 (fr) 2002-10-31 2002-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
PCT/FR2003/003262 WO2004042063A1 (fr) 2002-10-31 2003-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle ou l'obesite

Publications (1)

Publication Number Publication Date
ATE497003T1 true ATE497003T1 (de) 2011-02-15

Family

ID=32104388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767876T ATE497003T1 (de) 2002-10-31 2003-10-31 Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht

Country Status (12)

Country Link
US (3) US8859537B2 (de)
EP (1) EP1556489B1 (de)
JP (1) JP4852245B2 (de)
AT (1) ATE497003T1 (de)
AU (1) AU2003292310A1 (de)
CA (1) CA2503546C (de)
DE (1) DE60335892D1 (de)
DK (1) DK1556489T3 (de)
ES (1) ES2362092T3 (de)
FR (1) FR2846559B1 (de)
PT (1) PT1556489E (de)
WO (1) WO2004042063A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
WO2012024616A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
EP3952852A4 (de) * 2019-04-09 2023-01-04 The Trustees of Columbia University in the City of New York Prophylaktische wirksamkeit von serotonin-4-rezeptoragonisten gegen stress
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009828A1 (en) * 1992-11-03 1994-05-11 Synaptic Pharmaceutical Corporation Dna encoding a human serotonin receptor (5-ht4b) and uses thereof
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
WO1997029739A2 (en) * 1996-02-15 1997-08-21 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
EP1173168A2 (de) * 1999-04-28 2002-01-23 Respiratorius AB Verbindung zur verwendung als medikament zur behandling von krankheiten die durch fehlregulation der bronchienkontraktion gekennzeicht sind
GB9913850D0 (en) * 1999-06-14 1999-08-11 Janssen Pharmaceutica Nv Cloning and expression of a novel receptor
FR2811989A1 (fr) * 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Also Published As

Publication number Publication date
US9168250B2 (en) 2015-10-27
PT1556489E (pt) 2011-05-31
EP1556489A1 (de) 2005-07-27
JP4852245B2 (ja) 2012-01-11
DE60335892D1 (de) 2011-03-10
FR2846559B1 (fr) 2007-06-15
DK1556489T3 (da) 2011-05-16
WO2004042063A1 (fr) 2004-05-21
EP1556489B1 (de) 2011-01-26
US20130274293A1 (en) 2013-10-17
US8859537B2 (en) 2014-10-14
JP2006520319A (ja) 2006-09-07
WO2004042063A8 (fr) 2005-08-11
US20060116341A1 (en) 2006-06-01
FR2846559A1 (fr) 2004-05-07
CA2503546C (fr) 2014-02-11
US8436021B2 (en) 2013-05-07
US20090124592A1 (en) 2009-05-14
ES2362092T3 (es) 2011-06-28
CA2503546A1 (fr) 2004-05-21
AU2003292310A1 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
BRPI0416283A (pt) compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
ATE482966T1 (de) Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE497003T1 (de) Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht
ATE390130T1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
EP1844779A3 (de) Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne)
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
DE60334094D1 (de) Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden
BRPI0606502A2 (pt) compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos
ATE373014T1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung,die dieses enthalten
ATE364389T1 (de) Verfahren zur herstellung von extrakten aus pelargonium sidoides und/oder pelargonium reniforme
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE516038T1 (de) Metallcluster-nanoverbindungen zur behandlung von tumorerkrankungen
BRPI0514412A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, sua utilização e método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(gama) ppar(alfa)
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
RU2003118497A (ru) Способ лечения заболеваний слизистых оболочек
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556489

Country of ref document: EP